Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib

J Cancer Res Ther. 2020 Jul-Sep;16(4):919-921. doi: 10.4103/jcrt.JCRT_985_15.

Abstract

An 84-year-old male had a recurrence after surgical resection against Stage IIIA pulmonary adenocarcinoma and was treated with crizotinib due to harboring the anaplastic lymphoma kinase fusion gene. The patient exhibited crizotinib-induced interstitial lung disease (ILD), and alectinib was administered because of progressive disease. However, ILD appeared in both lungs again after alectinib treatment. This is the first case of ILD, resulting from alectinib administration after crizotinib-induced ILD. We should pay careful attention to patients who are treated with alectinib after crizotinib-induced ILD.

Keywords: Anaplastic lymphoma kinase; interstitial lung disease; lung cancer.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma of Lung / drug therapy*
  • Adenocarcinoma of Lung / genetics
  • Adenocarcinoma of Lung / pathology
  • Aged, 80 and over
  • Anaplastic Lymphoma Kinase / genetics
  • Carbazoles / adverse effects*
  • Carbazoles / therapeutic use
  • Crizotinib / adverse effects*
  • Crizotinib / therapeutic use
  • Humans
  • Lung Diseases, Interstitial / chemically induced*
  • Lung Diseases, Interstitial / genetics
  • Lung Diseases, Interstitial / pathology
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Male
  • Piperidines / adverse effects*
  • Piperidines / therapeutic use
  • Prognosis
  • Protein Kinase Inhibitors / adverse effects*
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Carbazoles
  • Piperidines
  • Protein Kinase Inhibitors
  • Crizotinib
  • ALK protein, human
  • Anaplastic Lymphoma Kinase
  • alectinib